drugset / Trial / NCT03475524

USE THE SYSTEMIC METFORMIN IN MELASMA

NCT03475524

Phase 4 Unknown 60 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

Melasma is a chronic and relapsing acquired dyschromia due to an increased epidermal-melanin unit activity that affects sun-exposed areas mainly in women throughout the reproductive years. It is more common in women, accounting for 90% of all cases.The majority of patients are in third and fourth decades of their life. There are several risk factors that influence its appearance including genetic predisposition,exposure to heat and UV radiation, pregnancy, and exogenous hormones (such as oral contraceptives,thyroid hormones, and hormone replacement therapy). Other factors implicated are phototoxic drugs, anticonvulsant medications,and the use of certain cosmetics. Types of melasma are epidermal, dermal and mixed according to location of melanin.

Timeline

Start
2019-04-01
Primary completion
2021-08
Completion
2021-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Metformin Small molecule 1000 mg Oral
Background Trichloroacetic acid Small molecule 25 % Topical